Company Wayland Group Corp. Canadian Securities Exchange
Equities
WAYL
CA9442041062
Pharmaceuticals
Business Summary
Sales per Business
USD in Million | 2016 | Weight | 2017 | Weight | Delta |
---|---|---|---|---|---|
Marijuana Production for Medical Purposes
100.0
%
| 3 | 100.0 % | 2 | 100.0 % | -18.98% |
Sales per region
USD in Million | 2016 | Weight | 2017 | Weight | Delta |
---|---|---|---|---|---|
Canada
100.0
%
| 3 | 100.0 % | 2 | 100.0 % | -18.98% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Dan Healey
COO | Chief Operating Officer | - | - |
Steven Bennett
CTO | Chief Tech/Sci/R&D Officer | - | - |
Compliance Officer | - | - | |
Geoff Kosar
SAM | Sales & Marketing | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 237,260,499 | 237,260,499 ( 100.00 %) | 0 | 100.00 % |
Company contact information
Wayland Group Corp.
845 Harrington Court Unit 3
L7N 3P3, Burlington
+289-288-6274
Sector
1st Jan change | Capi. | |
---|---|---|
+35.04% | 5.92B | |
-15.13% | 4.51B | |
-9.75% | 3.15B | |
+2.14% | 3.1B | |
-6.82% | 2.42B | |
+47.87% | 1.97B | |
-7.89% | 1.68B | |
+0.09% | 1.65B | |
-12.97% | 1.53B |